AlphAIAlphAI — Financial news for AI agents
rttnews.comOCT 82 min read$ANGO

AngioDynamics Reiterates FY27 Outlook; Appoints Eric Honroth President And CEO - Update

AngioDynamics (ANGO) reported Q1 results and reiterated its FY27 adjusted loss guidance of $0.29-$0.24 per share and net sales guidance of $336M-$341M. The company expects tariff impacts similar to FY26. Eric Honroth will become CEO on November 2, 2026, succeeding Jim Clemmer. ANGO stock is up 0.42% in pre-market trading.

Original reporting
rttnews.com
Published Oct 8, 2026, 11:36 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 1:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AngioDynamics Reiterates FY27 Outlook; Appoints Eric Honroth President And CEO - Update — source image
Source · rttnews.com
Decision brief

The 30-second read

$ANGONeutralMed
01

Why it matters

The reaffirmed guidance suggests earnings stability, while the leadership change may reduce execution risk, supporting a modest bullish stance.

02

Market read

First report of FY27 guidance and CEO appointment provides actionable insight for traders focusing on small‑cap medical device stocks.

03

What to watch

Potential tariff impacts and execution of the new CEO's strategy could affect future performance.

Relevance 7/10Novelty 7/10Timing: pre-market today

Background

AngioDynamics (NASDAQ: ANGO) reported Q1 results, reaffirmed FY27 guidance, and named Eric Honroth as President and CEO.

Company-level read

Ticker impact

$ANGONeutralHigh confidence
Context

AngioDynamics reiterated FY27 adjusted loss guidance and announced a new CEO, providing fresh guidance numbers and leadership change.

Expected impact

likely modest upside as market prices in stable guidance and leadership continuity

Evidence & confidence

The guidance range is unchanged, but the CEO appointment reduces uncertainty, prompting modest buying pressure.

Market effects

Sector

Stable guidance may reinforce expectations for the medical device sector's earnings outlook.

Regional

Limited to U.S. small‑cap medical device investors.

Global

Minimal global impact beyond sector peers.

Counterpoint

What could challenge this read

Investors could view unchanged guidance as a lack of growth momentum and short the stock.

Key entities

  • Company
    AngioDynamics, Inc.

    Medical device manufacturer reporting Q1 and FY27 outlook.

  • Executive
    Eric Honroth

    New President and CEO effective Nov 2, 2026.

Read at source← All news

Also covered by

4 outlets

Related articles

OCT 8
$ANGOMed

AngioDynamics Q1 Earnings Call Highlights

AngioDynamics (ANGO) reported Q1 revenue growth in NanoKnife, up 29% to $8.3M, with probe sales rising 24.1% and capital sales up 53.5%. The company expects AlphaReturn to expand its product line. Gross margin improved to 59.4%, and adjusted EBITDA increased to $5M. The company reaffirmed its fiscal 2027 outlook, expecting revenue of $336M-$341M and adjusted EBITDA of $13M-$16M.

finance.yahoo.com2 min
OCT 8
$ANGOHighAI 8/10

AngioDynamics Q1 FY2027 net loss narrows to $7.1M

AngioDynamics (NASDAQ: ANGO) reported Q1 FY2027 net loss of $7.1M, down from $10.9M YoY. Net sales rose 6.9% to $80.9M, with Med Tech sales up 13.2%. Adjusted EBITDA was $5.0M. The company announced Eric Honroth as new CEO, effective November 2, 2026. FDA approved IDE for RELIEF study on NanoKnife IRE for benign prostatic hyperplasia. Guidance reiterated: net sales $336M-$341M, adjusted EBITDA $13M-$16M.

stocktitan.net2 min
OCT 8
$ANGOMed

AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability

ANGIODYNAMICS INC (ANGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability Delivered its eighth consecutive quarter of double-digit Med Tech segment growth and positive adjusted EBITDA LATHAM, N.Y.--(BUSINESS

SEC EDGAR 8-K2 min